MASSDEVICE ON CALL — Baxter (NYSE:BAX) closed the books on a federal bribery investigation after regulators dropped the probe without finding wrongdoing, the company announced.
The FDA sent warning letters to Baxter (NYSE:BAX) this year, flagging infractions at an Illinois plant where Baxter makes its HomeChoice dialysis device and at a California plant that makes drug infusion pumps.
Illinois medical device maker Baxter‘s (NYSE:BAX) won European regulatory approval for its VIVIA hemodialysis system, designed for use in multiple settings and therapy regimens.